EXHIBIT 12
Baxter International Inc. and Subsidiaries
Computation of Ratio of Earnings to Fixed Charges
(unaudited — in millions, except ratios)
(unaudited — in millions, except ratios)
Years ended December 31, | 2007 | 2006 | 2005 | 2004 | 2003 | |||||||||||||||
Income from continuing operations before income taxes and cumulative effect of accounting changes | $2,114 | $1,746 | $1,444 | $430 | $1,129 | |||||||||||||||
Fixed charges | ||||||||||||||||||||
Interest costs (1) | 136 | 116 | 184 | 144 | 152 | |||||||||||||||
Estimated interest in rentals (2) | 52 | 49 | 46 | 50 | 51 | |||||||||||||||
Fixed charges as defined | 188 | 165 | 230 | 194 | 203 | |||||||||||||||
Adjustments to income | ||||||||||||||||||||
Interest costs capitalized | (12 | ) | (15 | ) | (18 | ) | (18 | ) | (37 | ) | ||||||||||
Net gains of less than majority-owned affiliates, net of dividends | — | (2 | ) | (6 | ) | (5 | ) | (23 | ) | |||||||||||
Income as adjusted | $2,290 | $1,894 | $1,650 | $601 | $1,272 | |||||||||||||||
Ratio of earnings to fixed charges (3) | 12.18 | 11.48 | 7.17 | 3.10 | 6.27 | |||||||||||||||
(1) | Excludes interest on uncertain tax positions under Financial Accounting Standards Board Interpretation No. 48, “Accounting for Uncertainty in Income Taxes — an Interpretation of FASB Statement 109.” | |
(2) | Represents the estimated interest portion of rents. | |
(3) | Excluding the following pre-tax special charges included in “Income from continuing operations”, the ratio of earnings to fixed charges was 13.18, 11.94, 7.47, 7.98, and 7.93 in 2007, 2006, 2005, 2004 and 2003, respectively. |
2007: | $70 million charge for restructuring, $56 million charge relating to litigation and $61 million of charges relating to acquired in-process and collaboration research and development. | |
2006: | $76 million charge relating to infusion pumps. | |
2005: | $109 million benefit relating to restructuring charge adjustments, $126 million of charges relating to infusion pumps and a $50 million charge relating to the exit of hemodialysis instrument manufacturing. | |
2004: | $543 million charge for restructuring, $289 million charge for impairments and $115 million for other special charges. | |
2003: | $337 million charge for restructuring. |